Skip to main content

Using multiplex immunophenotyping to understand anti-tumor immunity

18 Jun 2024
Translational Research
  • Studies utilizing flow cytometry have engendered multiple paradigms to understand T cell memory. How can these differing paradigms be utilized to enhance the duration anti-tumor immune responses? Is a consensus emerging as to what paradigms are most relevant?
  • The ability to immunophenotype cells with spatial resolution has enhanced our ability to understand the Tumor Microenvironment (TME). However, limited accessibility and limited tissue availability can hinder the use of microscopy. Can peripheral immunophenotyping help address these challenges? To what extent can peripheral immunophenotyping be used trusted as a proxy to understand how cells function in the TME?
  • Fluorescence-Activated Cell Sorting (FACS) can be used to isolate tumor-specific T cells from patients post-treatment and assess their functionality. Can such studies be trusted as reflective of the TME? Are there other approaches to better understand T cell functionality within the TME?
  • What are the most important unanswered questions that multiplexed immunophenotyping can help us address today?
Industry Expert
Chris Dupont, Associate Director (Clinical Translational Lead) - Adaptimmune